Cambium Bio
Sydney
About Cambium Bio
Cambium Medical Technologies, founded by four blood industry luminaries out of Emory University, Atlanta, Georgia (USA)--is focused on the development and commercialization of regenerative therapies derived from novel processed human platelets. Cambium is developing Elate Ocular a standardized, commercialized platelet derived biologic eye drop for dry eye syndrome (keratoconjunctivis sicca) as its first FDA approved therapy. Elate Ocular is an investigational drug and is not yet approved for sale in or outside the United States.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: Less than $1M
- Total funding: $7.0M
- Funding stage: IPO
- Last round: Post-IPO Equity (Dec 2024)
- Ticker: asx:CMB
- Website: cambiumbio.com
- Phone: +001 404-262-0905
Industries & Categories
Health Care, Health Diagnostics, Therapeutics
Canonical: https://fsome.com/organization/cambium-bio-211549 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.